Seth Lederman

Seth M. Birnbaum Joins Pharma Company Hallux Inc. Board of Directors

Retrieved on: 
Wednesday, May 18, 2022
Economics, HSG, Risk management, Infection, Patient, Bridgewater Associates, Amherst College, BA, Open Doors, Institutional investor, Philosophy, Onychomycosis, Safety, Seth Lederman, CFA, Pharmaceutical industry, Management, Toe

LAGUNA HILLS, Calif., May 18, 2022 /PRNewswire-PRWeb/ -- Hallux Inc, a clinical stage pharmaceutical company, announced today that following last month's initial closing of its $9.4 million Series A-2 financing round, veteran Bridgewater Associates Partner Seth M. Birnbaum has been appointed to its board of directors. Proceeds of the capital raise will be used to further fund the company's phase 2 clinical program evaluating Hallux Subungual Gel (HSG) for the treatment of onychomycosis (toenail fungus).

Key Points: 
  • LAGUNA HILLS, Calif., May 18, 2022 /PRNewswire-PRWeb/ -- Hallux Inc, a clinical stage pharmaceutical company, announced today that following last month's initial closing of its $9.4 million Series A-2 financing round, veteran Bridgewater Associates Partner Seth M. Birnbaum has been appointed to its board of directors.
  • Hallux CEO Mark Taylor said, "On behalf of our entire board, we are excited to have Seth join Hallux as a director.
  • Our board members are both personally invested in Hallux and extremely experienced in clinical development, specifically onychomycosis.
  • Seth M. Birnbaum, CFA is a 20-year veteran of Bridgewater Associates , where he is a partner and senior member of the investment team.

Fibromyalgia Drug Pipeline Market Research Report 2021 Featuring 13 Companies Developing Therapies - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 5, 2021
Health, Pharmaceutical, Tablet, Clinical trial, Discovery, MC-1 bomb, Simplex, United States, Tongue, Seth Lederman, Absorption, Therapy, Perception, Celecoxib, Pain, Tonix Pharmaceuticals, News, Mergers and acquisitions, SL, Famciclovir, DNA, Enzyme, Hydrogen chloride, Pharmaceutical industry, Vaccine

This Fibromyalgia - Pipeline Insight, 2021 provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Fibromyalgia pipeline landscape.

Key Points: 
  • This Fibromyalgia - Pipeline Insight, 2021 provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Fibromyalgia pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Fibromyalgia R&D.
  • 13+ key companies which are developing the therapies for Fibromyalgia.
  • The companies which have their Fibromyalgia drug candidates in the most advanced stage, i.e.

Tonix Pharmaceuticals Announces Agreement to Acquire Infectious Disease R&D Facility to Accelerate Development of Vaccines and Antiviral Drugs

Retrieved on: 
Tuesday, July 27, 2021
Seth Lederman, Tonix Pharmaceuticals, Vaccine

CHATHAM, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the signing of a Purchase and Sale Agreement to acquire an approximately 48,000 square foot research and development (R&D) facility in Frederick, MD to support Tonix’s expanding infectious disease pipeline, including TNX-1800, a live replicating viral vaccine designed to protect against COVID-19, TNX-801, a live vaccine designed to protect against smallpox and monkeypox, and TNX-3500, a small molecule antiviral to inhibit replication of SARS-CoV-2.

Key Points: 
  • Tonix agreed to purchase the R&D facility from Southern Research, a research collaboration partner for TNX-1800 and TNX-801 development.
  • The Fredrick facility will be a major expansion of our R&D capabilities, stated Seth Lederman, M.D., President and Chief Executive Officer of Tonix.
  • We believe this facility will ensure adequate resources and capacity to support and grow our pipeline of vaccines and antiviral therapeutics.
  • As with any pharmaceutical under development, there are significant risks in the development, regulatory approval, and commercialization of new products.

Tonix Pharmaceuticals Announces New Board Member, Carolyn E. Taylor

Retrieved on: 
Monday, July 19, 2021
Tonix Pharmaceuticals, Seth Lederman

NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix), a clinical-stage biopharmaceutical company, today announced the appointment of Carolyn E. Taylor to its Board of Directors, effective as of July 16, 2021.

Key Points: 
  • NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix), a clinical-stage biopharmaceutical company, today announced the appointment of Carolyn E. Taylor to its Board of Directors, effective as of July 16, 2021.
  • Seth Lederman, M.D., President and Chief Executive Officer of Tonix commented, We are pleased to welcome Carolyn E. Taylor to the Tonix Board.
  • We look forward to the insights Ms. Taylor will bring to the Board.
  • Its a pleasure to join a company with a strong sense of purpose coupled with such a dedicated, experienced management team, said Ms. Taylor.

Tonix Pharmaceuticals to Present at Raymond James Human Health Innovation Conference

Retrieved on: 
Wednesday, June 16, 2021
Life sciences, Tonix Pharmaceuticals, Biotechnology, Seth Lederman, Health sciences, Biopharmaceutical

CHATHAM, N.J., June 16, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present at the Raymond James Human Health Innovation Conference on June 23, 2021, at 8:00 a.m.

Key Points: 
  • CHATHAM, N.J., June 16, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present at the Raymond James Human Health Innovation Conference on June 23, 2021, at 8:00 a.m.
  • Investors interested in arranging a virtual meeting with the Companys management during the conference should contact the Raymond James conference coordinator.
  • A webcast of the presentation will be available under the IR Events tab of the Investors section of the Tonix website at www.tonixpharma.com .
  • About Tonix Pharmaceuticals Holding Corp.
    Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering.

Tonix Pharmaceuticals to Participate in BIO Digital Conference

Retrieved on: 
Thursday, June 10, 2021
Life sciences, Tonix Pharmaceuticals, Biotechnology, Health sciences, Seth Lederman, Biopharmaceutical

CHATHAM, N.J., June 10, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will participate in the BIO Digital Conference being held June 10-11 and 14-18, 2021.

Key Points: 
  • CHATHAM, N.J., June 10, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will participate in the BIO Digital Conference being held June 10-11 and 14-18, 2021.
  • The Companys presentation will be made through the BIO Digital Conference website and available on demand to registered participants during the conference at https://www.bio.org/events/bio-digital/sessions?sessionTypes=25903 .
  • Following the conference, the presentation will be available under the IR Events tab of the Investors section of the Tonix website at www.tonixpharma.com .
  • About Tonix Pharmaceuticals Holding Corp.
    Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering.

Tonix Pharmaceuticals Announces Presentation of Two Posters at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Retrieved on: 
Wednesday, May 26, 2021
Life sciences, Medical specialties, Health sciences, Immunology, Biopharmaceutical, Biotechnology, Pharmaceutical industry, Pharmacy, Vaccine, Autoimmunity, Tonix Pharmaceuticals, Seth Lederman

The Companys CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions.

Key Points: 
  • The Companys CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions.
  • Tonixs immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases.
  • Tonix reported positive efficacy data from animal studies of TNX-1800 in the first quarter of 2021.
  • All Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

Tonix Pharmaceuticals to Present at May Investor Summit Virtual Conference

Retrieved on: 
Wednesday, May 12, 2021
Life sciences, Tonix Pharmaceuticals, Seth Lederman, Biotechnology, Health sciences, Biopharmaceutical, Investor AB

b"CHATHAM, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present a company overview during the Q2 Investor Summit Virtual Conference on Monday, May 17, 2021 at 3:30 p.m. ET.\nInvestors interested in arranging a virtual meeting with the Company\xe2\x80\x99s management during the conference should contact the Investor Summit conference coordinator.

Key Points: 
  • b"CHATHAM, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present a company overview during the Q2 Investor Summit Virtual Conference on Monday, May 17, 2021 at 3:30 p.m. ET.\nInvestors interested in arranging a virtual meeting with the Company\xe2\x80\x99s management during the conference should contact the Investor Summit conference coordinator.
  • Tonix\xe2\x80\x99s portfolio is primarily composed of central nervous system (CNS) and immunology product candidates.
  • The Company\xe2\x80\x99s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions.
  • Tonix reported positive efficacy data from animal studies of TNX-1800 in the first quarter of 2021.

Tonix Pharmaceuticals to Present at Needham Virtual Healthcare Conference

Retrieved on: 
Wednesday, April 7, 2021
Life sciences, Tonix Pharmaceuticals, Biotechnology, Seth Lederman, Health sciences, Biopharmaceutical

CHATHAM, N.J., April 07, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present a company overview during the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 8:00 a.m.

Key Points: 
  • CHATHAM, N.J., April 07, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present a company overview during the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 8:00 a.m.
  • Investors interested in arranging a virtual meeting with the Companys management during the conference should contact the Needham conference coordinator.
  • A webcast of the presentation will be available under the IR Events tab of the Investors section of the Tonix website at www.tonixpharma.com .
  • Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering.

Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA on TNX-601 CR for the Treatment of Major Depressive Disorder

Retrieved on: 
Monday, March 22, 2021
Tonix Pharmaceuticals, Psychoactive drugs, Chemical compounds, Seth Lederman, Chloroarenes, Organic compounds, Tianeptine, Selective serotonin reuptake inhibitor, Bioequivalence

Tonixs TNX-601 CR is a novel oral formulation which is being developed as a potential treatment for MDD, posttraumatic stress disorder, and neurocognitive dysfunction associated with corticosteroid use.

Key Points: 
  • Tonixs TNX-601 CR is a novel oral formulation which is being developed as a potential treatment for MDD, posttraumatic stress disorder, and neurocognitive dysfunction associated with corticosteroid use.
  • We are pleased with the results of the FDA meeting on developing TNX-601 CR for the treatment of MDD and we look forward to advancing its clinical development, said Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals.
  • We believe that with respect to tianeptine, TNX-601 CR would meet the bioequivalence standard for daily dosing of these immediate release (IR) products.
  • Given tianetptines unique metabolic pathway, we believe that TNX-601 CR has a reduced risk of drug-drug interactions compared to SSRIs5.